Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Perspective Therapeutics' pipeline led by VMT-a-NET shows early potential, but adoption risks remain despite solid cash ...

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment ...

Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to trac ...

Q2 2025 Earnings Call Transcript August 6, 2025 Fortrea Holdings Inc. beats earnings expectations. Reported EPS is $0.19, ...

Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could reduce ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding sharehol ...

THE Philippine Council for Health Research and Development (PCHRD) is seeking stronger alignment between health research and policymaking as it hosts the 18th Philippine National Health Research ...

D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

National conference titled Connectomics-2025, focusing on the convergence of Omics, Bioinformatics, and Data Science for modern medical research, inaugurated ...